Mirati Therapeutics, Inc. (NASDAQ:MRTX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday.

MRTX has been the topic of a number of other research reports. Zacks Investment Research cut shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. ValuEngine upgraded shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 15th. Oppenheimer Holdings, Inc. assumed coverage on shares of Mirati Therapeutics in a report on Monday, September 18th. They set an “outperform” rating and a $18.00 price target on the stock. SunTrust Banks, Inc. reiterated a “buy” rating and set a $13.00 price target on shares of Mirati Therapeutics in a report on Thursday, October 12th. Finally, Leerink Swann increased their price target on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.14.

Shares of Mirati Therapeutics (MRTX) traded up $0.45 on Tuesday, reaching $15.50. 390,500 shares of the company’s stock were exchanged, compared to its average volume of 539,018. Mirati Therapeutics has a twelve month low of $2.70 and a twelve month high of $16.50.

Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. equities analysts expect that Mirati Therapeutics will post -2.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Reiterates Buy Rating for Mirati Therapeutics, Inc. (MRTX)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/14/hc-wainwright-reiterates-buy-rating-for-mirati-therapeutics-inc-mrtx.html.

In related news, SVP Jamie Christensen sold 7,499 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total transaction of $104,986.00. Following the transaction, the senior vice president now owns 10,169 shares in the company, valued at $142,366. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 12,269 shares of company stock worth $170,226. 5.10% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of MRTX. Baker BROS. Advisors LP bought a new position in Mirati Therapeutics during the third quarter valued at approximately $14,999,000. Boxer Capital LLC bought a new position in Mirati Therapeutics during the fourth quarter valued at approximately $63,934,000. Broadfin Capital LLC lifted its position in Mirati Therapeutics by 153.1% during the first quarter. Broadfin Capital LLC now owns 2,090,801 shares of the biotechnology company’s stock valued at $10,872,000 after purchasing an additional 1,264,800 shares during the period. Aviva Holdings Ltd. lifted its position in Mirati Therapeutics by 195.9% during the first quarter. Aviva Holdings Ltd. now owns 1,546,001 shares of the biotechnology company’s stock valued at $33,328,000 after purchasing an additional 1,023,501 shares during the period. Finally, Ghost Tree Capital LLC bought a new position in Mirati Therapeutics during the fourth quarter valued at approximately $7,900,000. Institutional investors own 59.49% of the company’s stock.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.